Pila Pharma (PILA) Investor Update summary

Clinical development and trial updates

• Developing an oral drug for type 2 diabetes, with potential in obesity and cardiovascular disease.

• Next clinical trial will be a dose escalation study to assess weight loss effects; results expected within a year from trial start, likely in 2025.

• Previous human trials have shown good safety and signs of efficacy; over 300 people have been tested.

• Ongoing preclinical collaboration with Uppsala University to explore cardiovascular benefits.

Financial status and funding

• Recent fundraising aimed to support expanded clinical trials; protocol changes may affect costs.

• No lock-up period for recent private placement; management does not intend to sell shares.

• Future financing rounds are possible, but no formal timeline is set.

Pipeline and strategic focus

• Pipeline includes diabetes/obesity, rare disease (erythromelalgia, with orphan drug designation in the US), and cardiovascular indications.

• Orphan drug plan is developed; proof-of-concept trial for erythromelalgia is a focus.

• Differentiation from competitors lies in targeting TRPV1, unlike others focusing on GLP-1 or amylin.